Literature DB >> 8971035

Susceptibility of human bone marrow cells and hematopoietic cell lines to coxsackievirus B3 infection.

T Vuorinen1, R Vainionpää, R Vanharanta, T Hyypiä.   

Abstract

Viremia is commonly observed in association with enterovirus infections, and during this phase viruses can be transmitted to secondary target organs in the body. It is not known, however, whether blood cells play a role in the pathogenesis of enterovirus infection supporting virus replication. Our earlier work (T. Vuorinen, R. Vainionpää, H. Kettinen, and T. Hyypiä, Blood 84:823-829, 1994) demonstrated that coxsackievirus B3 is able to replicate in representatives of B- and T-cell lines but not in a monocytic cell line or peripheral blood mononuclear cells, indicating that virus replication may depend on the differentiation and maturation stages of the cells. Therefore, we have broaden our studies and analyzed the susceptibility of granulocyte-macrophage CFU and hematopoietic cell lines with various differentiation and maturation stages to coxsackievirus B3 infection. Virus replication was detected in B- and T-cell lines with no direct correlation to the maturation stage. Granulocyte-macrophage CFU were also able to support virus multiplication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971035      PMCID: PMC191003     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  MULTIPLICATION OF POLIOVIRUS TYPE I IN PREPARATIONS OF HUMAN LEUKOCYTES AND ITS INHIBITION BY INTERFERON.

Authors:  I GRESSER; C CHANY
Journal:  J Immunol       Date:  1964-06       Impact factor: 5.422

2.  Persistence of enteroviral RNA in chronic fatigue syndrome is associated with the abnormal production of equal amounts of positive and negative strands of enteroviral RNA.

Authors:  L Cunningham; N E Bowles; R J Lane; V Dubowitz; L C Archard
Journal:  J Gen Virol       Date:  1990-06       Impact factor: 3.891

3.  Persistence of replicating coxsackievirus B3 in the athymic murine heart is associated with development of myocarditic lesions.

Authors:  S Sato; R Tsutsumi; A Burke; G Carlson; V Porro; Y Seko; K Okumura; R Kawana; R Virmani
Journal:  J Gen Virol       Date:  1994-11       Impact factor: 3.891

4.  Coxsackievirus B3 infection in human leukocytes and lymphoid cell lines.

Authors:  T Vuorinen; R Vainionpää; H Kettinen; T Hyypiä
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

5.  Poliovirus receptor on human blood cells: a possible extraneural site of poliovirus replication.

Authors:  M S Freistadt; H B Fleit; E Wimmer
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

6.  Replication of poliovirus in phytohemagglutinin-stimulated human lymphocytes.

Authors:  F T Willems; J L Melnick; W E Rawls
Journal:  J Virol       Date:  1969-05       Impact factor: 5.103

7.  Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation.

Authors:  K Klingel; C Hohenadl; A Canu; M Albrecht; M Seemann; G Mall; R Kandolf
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 8.  Structure and function of decay accelerating factor CD55.

Authors:  A Nicholson-Weller; C E Wang
Journal:  J Lab Clin Med       Date:  1994-04

9.  Persistent poliovirus infection: establishment and maintenance involve distinct mechanisms.

Authors:  S Borzakian; T Couderc; Y Barbier; G Attal; I Pelletier; F Colbère-Garapin
Journal:  Virology       Date:  1992-02       Impact factor: 3.616

10.  Coxsackievirus B3-induced production of tumor necrosis factor-alpha, IL-1 beta, and IL-6 in human monocytes.

Authors:  A Henke; C Mohr; H Sprenger; C Graebner; A Stelzner; M Nain; D Gemsa
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

View more
  8 in total

1.  Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers.

Authors:  D R Anderson; C M Carthy; J E Wilson; D Yang; D V Devine; B M McManus
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.

Authors:  D R Shafren; D T Williams; R D Barry
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Acanthamoeba castellanii promotion of in vitro survival and transmission of coxsackie b3 viruses.

Authors:  A Mattana; C Serra; E Mariotti; G Delogu; P L Fiori; P Cappuccinelli
Journal:  Eukaryot Cell       Date:  2006-04

4.  Parvovirus infection suppresses long-term repopulating hematopoietic stem cells.

Authors:  José C Segovia; Guillermo Guenechea; Jesús M Gallego; José M Almendral; Juan A Bueren
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis.

Authors:  Mary Anne Opavsky; Tami Martino; Marlene Rabinovitch; Josef Penninger; Chris Richardson; Martin Petric; Cathy Trinidad; Lisa Butcher; Janice Chan; Peter P Liu
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

6.  Binding to decay-accelerating factor is not required for infection of human leukocyte cell lines by enterovirus 70.

Authors:  Alain Haddad; M Reza Nokhbeh; David A Alexander; Sandra J Dawe; Christine Grisé; Naveed Gulzar; Kenneth Dimock
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  Coxsackievirus B3 infects the bone marrow and diminishes the restorative capacity of erythroid and lymphoid progenitors.

Authors:  Nadine Althof; J Lindsay Whitton
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

Review 8.  Enterovirus infections of the central nervous system.

Authors:  Ross E Rhoades; Jenna M Tabor-Godwin; Ginger Tsueng; Ralph Feuer
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.